Ma Yongxian, Katiyar Pragati, Jones Laundette P, Fan Saijun, Zhang Yiyu, Furth Priscilla A, Rosen Eliot M
Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20057-1469, USA.
Mol Endocrinol. 2006 Jan;20(1):14-34. doi: 10.1210/me.2004-0488. Epub 2005 Aug 18.
The progesterone receptor (PR) plays roles in normal mammary development and breast cancer formation, where it may exert both stimulatory and inhibitory actions. Previously, the breast cancer susceptibility gene product BRCA1 was found to interact with and inhibit the transcriptional activity of estrogen receptor-alpha. In this study, we found that exogenous wild-type BRCA1 inhibited the activity of the PR in transient transfection assays utilizing a mouse mammary tumor virus-Luc reporter. Wild-type BRCA1 inhibited the activity of endogenous PR in human breast cancer cells (T47D and MCF-7) and inhibited the activity of exogenous PR-A, PR-B, and [PR-A plus PR-B] isoforms. On the other hand, knockdown of endogenous BRCA1 using small interfering RNA enhanced the progesterone-stimulated activity of the PR by about 4-fold. We documented an in vivo association of the endogenous BRCA1 with PR isoforms A and B and a direct in vitro interaction between BRCA1 and PR, which was partially mapped. Whereas down-regulation of the coactivator p300 contributes to the BRCA1-mediated repression of estrogen receptor-alpha, this mechanism does not contribute to inhibition of PR activity, because exogenous p300 did not rescue the BRCA1 repression of PR activity. The BRCA1-PR interaction has functional consequences. Thus, we showed that BRCA1 inhibits the expression of various endogenous progesterone-responsive genes and inhibits progesterone-stimulated proliferation of T47D cells. Finally, exogenous progesterone caused an exaggerated proliferative response in the mammary glands of mice harboring a mammary-targeted conditional deletion of the full-length isoform of Brca1. These findings suggest that BRCA1 regulates the activity of progesterone, a major hormone of pregnancy that may also participate in mammary carcinogenesis.
孕激素受体(PR)在正常乳腺发育和乳腺癌形成过程中发挥作用,在这些过程中它可能具有刺激和抑制两种作用。此前,发现乳腺癌易感基因产物BRCA1可与雌激素受体α相互作用并抑制其转录活性。在本研究中,我们发现在利用小鼠乳腺肿瘤病毒-Luc报告基因的瞬时转染实验中,外源性野生型BRCA1抑制了PR的活性。野生型BRCA1抑制了人乳腺癌细胞(T47D和MCF-7)中内源性PR的活性,并抑制了外源性PR-A、PR-B以及[PR-A加PR-B]异构体的活性。另一方面,使用小干扰RNA敲低内源性BRCA1可使PR的孕激素刺激活性增强约4倍。我们记录了内源性BRCA1与PR异构体A和B在体内的关联以及BRCA1与PR在体外的直接相互作用,并且对该相互作用进行了部分定位。虽然共激活因子p300的下调有助于BRCA1介导的对雌激素受体α的抑制,但该机制对PR活性的抑制并无作用,因为外源性p300并不能挽救BRCA1对PR活性的抑制。BRCA1与PR的相互作用具有功能后果。因此,我们表明BRCA1抑制了各种内源性孕激素反应基因的表达,并抑制了孕激素刺激的T47D细胞增殖。最后,外源性孕激素在乳腺靶向条件性缺失全长Brca1异构体的小鼠乳腺中引起了过度的增殖反应。这些发现表明,BRCA1调节孕激素的活性——孕激素是妊娠的主要激素,也可能参与乳腺癌的发生。
J Mammary Gland Biol Neoplasia. 2019-5-18
Stem Cell Rev Rep. 2024-11
Dis Model Mech. 2023-11-1
Int J Mol Sci. 2022-8-23
NAR Genom Bioinform. 2022-2-2
Oncogene. 2005-3-10
Cancer Res. 2004-11-1
J Mammary Gland Biol Neoplasia. 2003-4
Mol Cell Biol. 2003-12
Trends Endocrinol Metab. 2003-10